Development of an optimised pancreatic cell tool kit to enable accelerated diabetes drug discovery

开发优化的胰腺细胞工具包以加速糖尿病药物的发现

• 批准号: 600387
• 金额: $ 37.52万
• 依托单位: DEFINIGEN LIMITED
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=600387
• 关键词: Development; optimised; pancreatic; cell; tool

Development of an optimised pancreatic cell tool kit to enable accelerated diabetes drug discovery. Diabetes drug discovery is constrained by the lack of availability of human pancreatic islets and their donor-dependent variability. We will develop pancreatic beta cell models for type 2 diabetes research from human induced pluripotent stem cells (hiPSCs), improving their maturity and function. Complementary CRISPR gene-edited disease models will also be generated. 3D cell culture systems will then be developed using automation compatible 96- or384-multiwell plate formats for high throughput screening and downstream drug evaluation. Market readiness of this platform will be evaluated by an industry beta testers.

开发优化的胰腺细胞工具包，以加速糖尿病药物的发现。糖尿病药物的发现受到人类胰岛缺乏可用性及其供体依赖性变异性的限制。我们将利用人类诱导多能干细胞（hiPSCs）开发用于2型糖尿病研究的胰腺β细胞模型，提高其成熟度和功能。互补的CRISPR基因编辑疾病模型也将被生成。3D细胞培养系统将使用自动化兼容的96-或384-多孔板格式进行高通量筛选和下游药物评估。该平台的市场准备情况将由行业测试人员进行评估。